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ABSTRACT
Objectives: 
The objective of this study was to determine the frequency of non-motor symptoms (NMS) in patients with Parkinson's 
disease (PD) and to compare frequency in mild and severe disease. Materials and methods: This descriptive 
observational study was done from January 2015 to June 2015 at Department of Neurology, Pakistan Institute of 
Medical Sciences, Islamabad. We used Non-Motor Symptom Questionnaire (NMS-Q); a validated scale using 30 
questions related to 9 different domains of symptoms. Results: 62 patients were enrolled in the final data set of study 
(male 46, Female 16) with average age of 62.4 years (range=33-80). Non-motor symptoms were reported very 
commonly in all stages of PD including urinary urgency (74%), dizziness (71%), memory problems (71%), sexual 
difficulty (69%), constipation (67%) and depression (62%). Only non-motor symptom that was statistically significantly 
higher in the severe stages was “reported falls” (Mild 39%, severe 61%, p < 0.01). Some were more common 
(lightheadedness, falls, sexual difficulty) while others were less (hyposmia). Conclusion: Non-motor symptoms are 
very common in Pakistani population of PD and are seen equally in mild and severe PD with exception of “reported 
falls”. The high prevalence of non-motor symptoms (especially in mild stages) should be kept in mind while managing 
PD. Furthermore, there may be the likely need for a culturally appropriate screening scale for our population. 
Keywords: 
Parkinson Disease, Non-motor symptoms, Pakistani population, NMS-Q, falls.
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INTRODUCTION
Parkinson's (PD) is the second most common 
neurodegenerative disorder. Its risk increases with 
advancing age. Parkinson’s Disease has been known 
since ancient times with the earliest mention in Indian 
medical manuscripts Ayeur Veda around 1000BC as 
“Kampavata.” 1, 2 It was named after James Parkinson 
who wrote a detailed monograph titled “an easy on 
shaking palsy” in 1817. 2, 3 European PD association 
estimates prevalence of PD as 6.3 million worldwide, 
affecting all races and cultures. Prevalence in Pakistan 
has been estimated to be 0.4 million by Pakistan 
Parkinson Disease Society. 4
Since its first description to until recently, it’s been 
largely dealt as a motor disease involving dopaminergic 
deficit. However various non-motor symptoms have 
been recognized over the years in PD including 
symptoms of gastrointestinal system, urinary system, 
sleep disturbance, psychiatric, sensory and cognitive 
impairment.5 The exact etiology has not been fully 
elucidated but there is evidence of involvement of 
non-dopaminergic pathways (such as cholinergic and 
serotonergic). Non-motor symptoms often precede 
motor symptoms by up to several decades, most 
commonly olfactory dysfunction (hyposmia), Rapid Eye 
Movement (REM) sleep behavior disorder (RBD), 
constipation, depression, and pain.6 Non-motor 
symptoms may be classified based on neurotransmitter 
pathways involved however most of them involve wide 
spread connections within the brain and thus hard to 
be classified separately. The non- motor symptoms are 
an integral part of the disease but are generally under 
recognized by the treating physician and under reported 
by the patients. Assessment of non-motor symptoms 
I & II) compared to younger population. None were 
seen in Stage 5. Similarly, looking at Stage distribution 
between males and females, males were 
proportionately more in mild disease (Stage I & II) in 
comparison with females (males 60%, females 25%) 
(Figure 2 & 3).
Figure 2: Stages of PD with age distribution
Figure 3: Gender Distribution of severity of PD
The urinary symptoms (urgency and nocturia) were 
most frequent (74.1% and 51.6% respectively) (see 
Table1). The gastro-intestinal symptoms were next in 
frequency with constipation being most common at 
67.7%. Neuropsychiatric symptoms were considerably 
high, including memory problems, low mood, anxiety 
and abnormal libido (71%, 62.9%, 51.6%, 67.7% in 
respective order). Autonomic symptoms like feeling 
light-headed and falling as a result were common (71% 
and 66.1%) while swelling of legs was uncommon at 
29%. Difficulty in performing sex was reported by 
67.7%. The sleep related problems also showed 
significantly high frequency with difficulty staying asleep 
being 58.1% and Restless Leg Syndrome being 59.7%, 
while unexplained pains and unexplained weight 
change were reported to be 61.3% and 38.7% 
respectively. Symptoms like dribbling saliva, double 
vision, dysphagia and hyposmia were in frequency of 
32.3%, 29%, 35.5% and 37.1% respectively. The p 
value was only significant for falling (p<0.01) when 
comparison was done between frequency of non-motor 
symptoms for mild and severe Parkinson’s Disease. The 
complete list of questions asked and frequency of 
symptoms is listed in Table 1. 
Table 1. Frequency of Non-Motor Symptoms
DISCUSSION
In this study we highlight the overall high frequency of 
NMS in PD in Pakistani population, and their 
comparison between mild and severe disease. Some of 
the components differ in frequency compared to other 
studies carried out around the world which will be 
discussed below.
In our study the highest overall NMS was found to be 
urinary urgency at 74%, comparatively higher than 
other studies. Bonnet et al. in 2012 described the 
urinary urgency in more than 50% of patients and Khoo 
et al. described urinary urgency in spectrum of NMS in 
Early PD at 46 %.6, 10 Constipation was the next 
frequent NMS found in this study at 67.7%. This was 
higher than study of Bonnet et al (45 to 60%), but 
similar to studies by Khoo et al (67%) and Azmin et al 
(67%) who looked at Malaysian population.6, 10, 11 
There was no significant difference between mild versus 
severe disease in our study; however study carried out 
in Italy (PRIAMO), constipation was found to be lower in 
Stage 1 (37%) and much higher in Stage 5 (73%). The 
constipation is treated in PD in usual manner like 
avoiding dehydration, use of laxatives and judicious use 
of fiber. 11
Neuropsychiatric symptoms (low mood and memory 
impairment) involve cholinergic pathways and may 
predate onset of clinical PD with motor symptoms.8, 9, 10, 
11, 12 We found neuropsychiatric symptoms like 
forgetting things and low mood was common (71% and 
62% respectively), with no significant difference 
between mild and severe disease (p 0.47 and 0.6 
respectively) (Table 1). Other studies have reported 
slightly lower incidences of 53-67%.9, 10, 11, 12 The 
dopamine effect is variable on psychiatric domain, with 
some patients responding positively while in others the 
effect remains unpredictable. Depression is linked with 
mortality and morbidity.12, 13, 14 It needs to be addressed 
properly at every stage of Parkinson’s disease and 
should be treated aggressively.
Sexual problems were also reported very high in our 
cohort in the form of decreased libido (67.7%) and 
difficulty in performance (69.4%) with no difference in 
frequency between mild and severe (p 0.7 and 0.2 
respectively) (Table 1). According to Bronner et al., the 
sex problems correlated more with severity of motor 
disease and male gender compared with age, 
depression and use of L-dopa.15 Khoo et al. reported 
significantly lower incidence of impaired libido and 
sexual dysfunction (17% and 28% respectively).10 
Similarly Azmin et al. reported it to be only 8%.11 One 
explanation of such marked difference could be 
different culture and social norms and biases against 
reporting. It is pertinent that this topic should be 
approached with due respect with the patient and 
managed appropriately.16
Among all the NMS, incidence of falling was the only 
reported symptom that was statistically significant (p< 
0.01) between mild and severe disease in our study. 
Fear of falling has been shown to be directly related to 
actual falling.16 Orthostatic hypotension (feeling light 
headed and dizziness) were present in 71%, and falling 
was also common at 66.1%. The incidence of these 
symptoms was extremely low in PRIAMO study (14.2% 
and 1% respectively).12 Khoo et al. reported somewhat 
higher number but still lower than our population (33% 
and 23% respectively).10 Sleep related problems 
(insomnia and Restless Leg Syndrome (RLS) were 
present in frequency of 58.1% and 59.7% (Table 1) 
with no difference in mild and severe disease (p 0.1 
and 0.4 respectively). This is similar to some studies 
such as study in Norwegian population reported 
incidence of sleep problems to be 60%.17,18 Another 
study by Prudon et al. looking at primary sleep disorder 
prevalence in patients with newly diagnosed 
Parkinson's disease reported similar results.19
The prevalence of self-reported hyposmia was only 
23%. This is in contrast to other studies which report 
this finding to be almost universal such as Xiao et al. 
described its prevalence of almost 90% while another 
study by Haehner reported it to be 95%.20, 21 This gross 
difference in the prevalence can be explained by the 
fact that simple question may not reveal the underlying 
problem unless tested by specific kits.21 Since 
hyposmia in recent trials has been shown to be a 
predictor of PD as well as dementia, it suggests a need 
for a better designed screening question for hyposmia 
as it pertains to our population to carry out further 
research in our population. 22, 23, 24
Our study had some limitations including gender bias 
with males being more common than females (ratio 
3:1), slightly more than western population (2:1) and 
likely represent culture bias (men more likely to seek 
treatment). Similarly, we noticed men to be in relatively 
milder disease compared with females. This may 
represent a treatment bias (where females are less 
likely to take medications or seek early treatment) and 
may also represent less access to healthcare by 
females (considered at-risk population). We also used 
a questionnaire not designed or validated in our 
population due to lack of such. The study population 
was small number and having a single site may have 
resulted in selection bias (studying only patients 
presenting to our hospital). 
CONCLUSION
We have shown that non-motor symptoms are 
extremely common in Parkinson’s disease in Pakistani 
population and the frequency of symptoms is similar in 
mild and severe disease except for frequent falls (more 
common in severe Disease)."This is in contrast to 
findings in other population groups with many 
symptoms being much more common in our population 
(such as orthostatic hypotension and falls). Others are 
either lower or more difficult to screen (such as 
hyposmia)." This highlights the strong need for larger 
scale studies to understand the incidence and the likely 
need for a culturally appropriate screening scale for our 
population.
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should be a part of management of PD and there are 
many validated tools available such as Non-Motor 
Symptom Questionnaire (NMSQ), Non-motor 
Symptoms Survey (NMSS),EQ -5D, Parkinson Disease 
Questionnaire(PDQ)39.7
The frequency of non-motor symptoms in Pakistani PD 
population is not known (though assumed to be similar 
to western population). The non-motor symptoms are 
also considered to be a problem of severe disease and 
thus routinely ignored in early disease by practicing 
physicians. In this study we intended to find the 
frequency of non-motor symptoms in Parkinson’s 
Disease and compare frequency between mild and 
severe disease.8,9 
MATERIALS AND METHODS
This study was a cross-sectional, observational, 
descriptive study; carried out on population of PD 
patients presenting to Outpatient clinics at Department 
of Neurology, Pakistan Institute of Medical Sciences 
(PIMS), Islamabad (a Tertiary Care Center). This study 
was internally funded and approved by the local ethics 
committee in accordance with Declaration of Helsinki.
 
All the patients who full-filled the clinical criteria of 
Parkinson’s Disease were included in the study 
according to UK Brain Bank Criteria (Annexure I).10 
Other inclusion parameters were age ≥ 18 years, able 
to give consent and able to answer questions 
independently or with help. Exclusion criteria were 
concern for atypical Parkinson’s, history of psychiatric 
disease or co-morbid conditions that could contribute 
to NMS like diabetes mellitus. Mild Parkinson’s Disease 
was defined as stage I&II of Hoehn and Yahr scale while 
severe disease was defined as stage III, IV & V of Hoehn 
and Yahr scale.11 Informed consent was obtained from 
the patients. The data was recorded with following 
variables: demographic details; age and gender, staging 
of Parkinson’s Disease according to Hoehn and Yahr 
Scale (Figure 1). We used Non-Motor Symptom 
Questionnaire (NMS-Q); a validated scale using 30 
questions related to 9 different domains of symptoms 
(Annexure II). 
The NMS-Q was filled by the patient either 
independently or assisted by family member(s). Where 
there was language problem, the author helped in 
translating the questionnaire to the patient.10
Figure 1: Hoehn &Yahr Scale of PD
Statistical Analysis
Data was analysed through SPSS version 17. The 
numerical data was expressed as mean and standard 
deviation (SD). The categorical data was expressed as 
frequency and percentages. Pearson’s Chi square test 
was used to compare the frequency of NMS in mild and 
severe disease. A p-value of less than 0.05 was 
considered statistically significant.
RESULTS
Statistical Analysis
Data was analysed through SPSS version 17. The 
numerical data was expressed as mean and standard 
deviation (SD). The categorical data was expressed as 
frequency and percentages. Pearson’s Chi square test 
was used to compare the frequency of NMS in mild and 
severe disease. A p-value of less than 0.05 was 
considered statistically significant.
RESULTS
Over the course of the study, 81 patients were 
screened. Those fulfilling the criteria for the study were 
included in the final data set. A total of 62 patients with 
Parkinson’s Disease were recruited over 6 months 
period. The average age was 62.4 ± 11.57 years with 
youngest being 33 years and oldest 80 years of age. 
Males were more common (n=46, 74.1%) then 
females (n=16, 25.8%) with a ration of 3:1.
13 Patients were aged less than 60 (young onset PD) 
including 3 patients in stages II and IV each and 7 in 
stage III. No patient was seen in stage I (likely cultural 
bias, as very early PD does not seek treatment 
potentially from lack of awareness and other 
differences). Majority of patients were above age 60 
(n=49) and had relatively milder disease (59% in stage 
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INTRODUCTION
Parkinson's (PD) is the second most common 
neurodegenerative disorder. Its risk increases with 
advancing age. Parkinson’s Disease has been known 
since ancient times with the earliest mention in Indian 
medical manuscripts Ayeur Veda around 1000BC as 
“Kampavata.” 1, 2 It was named after James Parkinson 
who wrote a detailed monograph titled “an easy on 
shaking palsy” in 1817. 2, 3 European PD association 
estimates prevalence of PD as 6.3 million worldwide, 
affecting all races and cultures. Prevalence in Pakistan 
has been estimated to be 0.4 million by Pakistan 
Parkinson Disease Society. 4
Since its first description to until recently, it’s been 
largely dealt as a motor disease involving dopaminergic 
deficit. However various non-motor symptoms have 
been recognized over the years in PD including 
symptoms of gastrointestinal system, urinary system, 
sleep disturbance, psychiatric, sensory and cognitive 
impairment.5 The exact etiology has not been fully 
elucidated but there is evidence of involvement of 
non-dopaminergic pathways (such as cholinergic and 
serotonergic). Non-motor symptoms often precede 
motor symptoms by up to several decades, most 
commonly olfactory dysfunction (hyposmia), Rapid Eye 
Movement (REM) sleep behavior disorder (RBD), 
constipation, depression, and pain.6 Non-motor 
symptoms may be classified based on neurotransmitter 
pathways involved however most of them involve wide 
spread connections within the brain and thus hard to 
be classified separately. The non- motor symptoms are 
an integral part of the disease but are generally under 
recognized by the treating physician and under reported 
by the patients. Assessment of non-motor symptoms 
I & II) compared to younger population. None were 
seen in Stage 5. Similarly, looking at Stage distribution 
between males and females, males were 
proportionately more in mild disease (Stage I & II) in 
comparison with females (males 60%, females 25%) 
(Figure 2 & 3).
Figure 2: Stages of PD with age distribution
Figure 3: Gender Distribution of severity of PD
The urinary symptoms (urgency and nocturia) were 
most frequent (74.1% and 51.6% respectively) (see 
Table1). The gastro-intestinal symptoms were next in 
frequency with constipation being most common at 
67.7%. Neuropsychiatric symptoms were considerably 
high, including memory problems, low mood, anxiety 
and abnormal libido (71%, 62.9%, 51.6%, 67.7% in 
respective order). Autonomic symptoms like feeling 
light-headed and falling as a result were common (71% 
and 66.1%) while swelling of legs was uncommon at 
29%. Difficulty in performing sex was reported by 
67.7%. The sleep related problems also showed 
significantly high frequency with difficulty staying asleep 
being 58.1% and Restless Leg Syndrome being 59.7%, 
while unexplained pains and unexplained weight 
change were reported to be 61.3% and 38.7% 
respectively. Symptoms like dribbling saliva, double 
vision, dysphagia and hyposmia were in frequency of 
32.3%, 29%, 35.5% and 37.1% respectively. The p 
value was only significant for falling (p<0.01) when 
comparison was done between frequency of non-motor 
symptoms for mild and severe Parkinson’s Disease. The 
complete list of questions asked and frequency of 
symptoms is listed in Table 1. 
Table 1. Frequency of Non-Motor Symptoms
DISCUSSION
In this study we highlight the overall high frequency of 
NMS in PD in Pakistani population, and their 
comparison between mild and severe disease. Some of 
the components differ in frequency compared to other 
studies carried out around the world which will be 
discussed below.
In our study the highest overall NMS was found to be 
urinary urgency at 74%, comparatively higher than 
other studies. Bonnet et al. in 2012 described the 
urinary urgency in more than 50% of patients and Khoo 
et al. described urinary urgency in spectrum of NMS in 
Early PD at 46 %.6, 10 Constipation was the next 
frequent NMS found in this study at 67.7%. This was 
higher than study of Bonnet et al (45 to 60%), but 
similar to studies by Khoo et al (67%) and Azmin et al 
(67%) who looked at Malaysian population.6, 10, 11 
There was no significant difference between mild versus 
severe disease in our study; however study carried out 
in Italy (PRIAMO), constipation was found to be lower in 
Stage 1 (37%) and much higher in Stage 5 (73%). The 
constipation is treated in PD in usual manner like 
avoiding dehydration, use of laxatives and judicious use 
of fiber. 11
Neuropsychiatric symptoms (low mood and memory 
impairment) involve cholinergic pathways and may 
predate onset of clinical PD with motor symptoms.8, 9, 10, 
11, 12 We found neuropsychiatric symptoms like 
forgetting things and low mood was common (71% and 
62% respectively), with no significant difference 
between mild and severe disease (p 0.47 and 0.6 
respectively) (Table 1). Other studies have reported 
slightly lower incidences of 53-67%.9, 10, 11, 12 The 
dopamine effect is variable on psychiatric domain, with 
some patients responding positively while in others the 
effect remains unpredictable. Depression is linked with 
mortality and morbidity.12, 13, 14 It needs to be addressed 
properly at every stage of Parkinson’s disease and 
should be treated aggressively.
Sexual problems were also reported very high in our 
cohort in the form of decreased libido (67.7%) and 
difficulty in performance (69.4%) with no difference in 
frequency between mild and severe (p 0.7 and 0.2 
respectively) (Table 1). According to Bronner et al., the 
sex problems correlated more with severity of motor 
disease and male gender compared with age, 
depression and use of L-dopa.15 Khoo et al. reported 
significantly lower incidence of impaired libido and 
sexual dysfunction (17% and 28% respectively).10 
Similarly Azmin et al. reported it to be only 8%.11 One 
explanation of such marked difference could be 
different culture and social norms and biases against 
reporting. It is pertinent that this topic should be 
approached with due respect with the patient and 
managed appropriately.16
Among all the NMS, incidence of falling was the only 
reported symptom that was statistically significant (p< 
0.01) between mild and severe disease in our study. 
Fear of falling has been shown to be directly related to 
actual falling.16 Orthostatic hypotension (feeling light 
headed and dizziness) were present in 71%, and falling 
was also common at 66.1%. The incidence of these 
symptoms was extremely low in PRIAMO study (14.2% 
and 1% respectively).12 Khoo et al. reported somewhat 
higher number but still lower than our population (33% 
and 23% respectively).10 Sleep related problems 
(insomnia and Restless Leg Syndrome (RLS) were 
present in frequency of 58.1% and 59.7% (Table 1) 
with no difference in mild and severe disease (p 0.1 
and 0.4 respectively). This is similar to some studies 
such as study in Norwegian population reported 
incidence of sleep problems to be 60%.17,18 Another 
study by Prudon et al. looking at primary sleep disorder 
prevalence in patients with newly diagnosed 
Parkinson's disease reported similar results.19
The prevalence of self-reported hyposmia was only 
23%. This is in contrast to other studies which report 
this finding to be almost universal such as Xiao et al. 
described its prevalence of almost 90% while another 
study by Haehner reported it to be 95%.20, 21 This gross 
difference in the prevalence can be explained by the 
fact that simple question may not reveal the underlying 
problem unless tested by specific kits.21 Since 
hyposmia in recent trials has been shown to be a 
predictor of PD as well as dementia, it suggests a need 
for a better designed screening question for hyposmia 
as it pertains to our population to carry out further 
research in our population. 22, 23, 24
Our study had some limitations including gender bias 
with males being more common than females (ratio 
3:1), slightly more than western population (2:1) and 
likely represent culture bias (men more likely to seek 
treatment). Similarly, we noticed men to be in relatively 
milder disease compared with females. This may 
represent a treatment bias (where females are less 
likely to take medications or seek early treatment) and 
may also represent less access to healthcare by 
females (considered at-risk population). We also used 
a questionnaire not designed or validated in our 
population due to lack of such. The study population 
was small number and having a single site may have 
resulted in selection bias (studying only patients 
presenting to our hospital). 
CONCLUSION
We have shown that non-motor symptoms are 
extremely common in Parkinson’s disease in Pakistani 
population and the frequency of symptoms is similar in 
mild and severe disease except for frequent falls (more 
common in severe Disease)."This is in contrast to 
findings in other population groups with many 
symptoms being much more common in our population 
(such as orthostatic hypotension and falls). Others are 
either lower or more difficult to screen (such as 
hyposmia)." This highlights the strong need for larger 
scale studies to understand the incidence and the likely 
need for a culturally appropriate screening scale for our 
population.
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should be a part of management of PD and there are 
many validated tools available such as Non-Motor 
Symptom Questionnaire (NMSQ), Non-motor 
Symptoms Survey (NMSS),EQ -5D, Parkinson Disease 
Questionnaire(PDQ)39.7
The frequency of non-motor symptoms in Pakistani PD 
population is not known (though assumed to be similar 
to western population). The non-motor symptoms are 
also considered to be a problem of severe disease and 
thus routinely ignored in early disease by practicing 
physicians. In this study we intended to find the 
frequency of non-motor symptoms in Parkinson’s 
Disease and compare frequency between mild and 
severe disease.8,9 
MATERIALS AND METHODS
This study was a cross-sectional, observational, 
descriptive study; carried out on population of PD 
patients presenting to Outpatient clinics at Department 
of Neurology, Pakistan Institute of Medical Sciences 
(PIMS), Islamabad (a Tertiary Care Center). This study 
was internally funded and approved by the local ethics 
committee in accordance with Declaration of Helsinki.
 
All the patients who full-filled the clinical criteria of 
Parkinson’s Disease were included in the study 
according to UK Brain Bank Criteria (Annexure I).10 
Other inclusion parameters were age ≥ 18 years, able 
to give consent and able to answer questions 
independently or with help. Exclusion criteria were 
concern for atypical Parkinson’s, history of psychiatric 
disease or co-morbid conditions that could contribute 
to NMS like diabetes mellitus. Mild Parkinson’s Disease 
was defined as stage I&II of Hoehn and Yahr scale while 
severe disease was defined as stage III, IV & V of Hoehn 
and Yahr scale.11 Informed consent was obtained from 
the patients. The data was recorded with following 
variables: demographic details; age and gender, staging 
of Parkinson’s Disease according to Hoehn and Yahr 
Scale (Figure 1). We used Non-Motor Symptom 
Questionnaire (NMS-Q); a validated scale using 30 
questions related to 9 different domains of symptoms 
(Annexure II). 
The NMS-Q was filled by the patient either 
independently or assisted by family member(s). Where 
there was language problem, the author helped in 
translating the questionnaire to the patient.10
Figure 1: Hoehn &Yahr Scale of PD
Statistical Analysis
Data was analysed through SPSS version 17. The 
numerical data was expressed as mean and standard 
deviation (SD). The categorical data was expressed as 
frequency and percentages. Pearson’s Chi square test 
was used to compare the frequency of NMS in mild and 
severe disease. A p-value of less than 0.05 was 
considered statistically significant.
RESULTS
Statistical Analysis
Data was analysed through SPSS version 17. The 
numerical data was expressed as mean and standard 
deviation (SD). The categorical data was expressed as 
frequency and percentages. Pearson’s Chi square test 
was used to compare the frequency of NMS in mild and 
severe disease. A p-value of less than 0.05 was 
considered statistically significant.
RESULTS
Over the course of the study, 81 patients were 
screened. Those fulfilling the criteria for the study were 
included in the final data set. A total of 62 patients with 
Parkinson’s Disease were recruited over 6 months 
period. The average age was 62.4 ± 11.57 years with 
youngest being 33 years and oldest 80 years of age. 
Males were more common (n=46, 74.1%) then 
females (n=16, 25.8%) with a ration of 3:1.
13 Patients were aged less than 60 (young onset PD) 
including 3 patients in stages II and IV each and 7 in 
stage III. No patient was seen in stage I (likely cultural 
bias, as very early PD does not seek treatment 
potentially from lack of awareness and other 
differences). Majority of patients were above age 60 
(n=49) and had relatively milder disease (59% in stage 
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Non-motor Symptoms All patients Mild PD 
(I/ II) 
Severe PD 
(III/ IV) 
p value 
Urinary Urgency 46 (74.1) 25 (54.3) 21 (45.7) 0.46 
Nocturia 32 (51.6) 14 (43.7) 18 (56.2) 0.54 
Hyposmia 23 (37.1) 13 (56.5) 10 (43.5) 0.55 
Dysphagia 22 (35.5) 13 (59.1) 09 (40.9) 0.38 
Nausea/ vomiting 06 (9.7) 04 (66.7) 02 (33.3) 0.43 
Constipation 42 (67.7) 24 (57.1) 18 (42.9) 0.20 
Incontinence 18 (29.0) 08 (44.4) 10 (55.6) 0.47 
Tenesmus 27 (43.5) 13 (48.1) 14 (51.9) 0.63 
Memory impairment 44 (71.0) 24 (54.5) 20 (45.5) 0.47 
Loss of interest 25 (40.3) 14 (56.0) 11 (44.0) 0.57 
Hallucinations 23 (37.1) 15 (65.2) 8 (34.8) 0.10 
Loss of concentration 25 (40.3) 15 (60.0) 10 (40.0) 0.27 
Low mood 39 (62.9) 21 (53.8) 18 (46.2) 0.64 
Anxiety 32 (51.6) 15 (46.9) 17 (53.1) 0.44 
Libido 42 (67.7) 21 (50.0) 21 (50.0) 0.71 
Sexual dysfunction 43 (69.4) 20 (46.5) 23 (53.5) 0.22 
Delusions 20 (32.3) 09 (45.0) 11 (55.0) 0.47 
Somnolence 23 (37.1) 12 (52.2) 11 (47.8) 0.94 
Insomnia 36 (58.1) 17 (47.2) 19 (52.8) 0.41 
Nightmares 26 (41.9) 14 (53.8) 12 (46.2) 0.76 
Parasomnia 22 (35.5) 12 (54.5) 10 (45.5) 0.73 
Restless legs 37 (59.7) 16 (43.2) 21 (56.8) 0.10 
Orthostatic hypotension 44 (71.0) 21 (47.7) 23 (52.3) 0.33 
Falls 41 (66.1) 16 (39.0) 25 (61.0) <0.01* 
Pedal edema 18 (29.0) 10 (55.6) 08 (44.4) 0.69 
Excessive sweating  23 (37.1) 14 (60.9) 09 (39.1) 0.26 
Double vision 18 (29.0) 08 (44.4) 10 (55.6) 0.47 
Unexplained pains 38 (61.3) 19 (50.0) 19 (50.0) 0.74 
Weight change 24 (38.7) 09 (37.5) 15 (62.5) 0.07 
Drooling 20 (32.3) 10 (50.0) 10 (50.0) 0.86 
INTRODUCTION
Parkinson's (PD) is the second most common 
neurodegenerative disorder. Its risk increases with 
advancing age. Parkinson’s Disease has been known 
since ancient times with the earliest mention in Indian 
medical manuscripts Ayeur Veda around 1000BC as 
“Kampavata.” 1, 2 It was named after James Parkinson 
who wrote a detailed monograph titled “an easy on 
shaking palsy” in 1817. 2, 3 European PD association 
estimates prevalence of PD as 6.3 million worldwide, 
affecting all races and cultures. Prevalence in Pakistan 
has been estimated to be 0.4 million by Pakistan 
Parkinson Disease Society. 4
Since its first description to until recently, it’s been 
largely dealt as a motor disease involving dopaminergic 
deficit. However various non-motor symptoms have 
been recognized over the years in PD including 
symptoms of gastrointestinal system, urinary system, 
sleep disturbance, psychiatric, sensory and cognitive 
impairment.5 The exact etiology has not been fully 
elucidated but there is evidence of involvement of 
non-dopaminergic pathways (such as cholinergic and 
serotonergic). Non-motor symptoms often precede 
motor symptoms by up to several decades, most 
commonly olfactory dysfunction (hyposmia), Rapid Eye 
Movement (REM) sleep behavior disorder (RBD), 
constipation, depression, and pain.6 Non-motor 
symptoms may be classified based on neurotransmitter 
pathways involved however most of them involve wide 
spread connections within the brain and thus hard to 
be classified separately. The non- motor symptoms are 
an integral part of the disease but are generally under 
recognized by the treating physician and under reported 
by the patients. Assessment of non-motor symptoms 
I & II) compared to younger population. None were 
seen in Stage 5. Similarly, looking at Stage distribution 
between males and females, males were 
proportionately more in mild disease (Stage I & II) in 
comparison with females (males 60%, females 25%) 
(Figure 2 & 3).
Figure 2: Stages of PD with age distribution
Figure 3: Gender Distribution of severity of PD
The urinary symptoms (urgency and nocturia) were 
most frequent (74.1% and 51.6% respectively) (see 
Table1). The gastro-intestinal symptoms were next in 
frequency with constipation being most common at 
67.7%. Neuropsychiatric symptoms were considerably 
high, including memory problems, low mood, anxiety 
and abnormal libido (71%, 62.9%, 51.6%, 67.7% in 
respective order). Autonomic symptoms like feeling 
light-headed and falling as a result were common (71% 
and 66.1%) while swelling of legs was uncommon at 
29%. Difficulty in performing sex was reported by 
67.7%. The sleep related problems also showed 
significantly high frequency with difficulty staying asleep 
being 58.1% and Restless Leg Syndrome being 59.7%, 
while unexplained pains and unexplained weight 
change were reported to be 61.3% and 38.7% 
respectively. Symptoms like dribbling saliva, double 
vision, dysphagia and hyposmia were in frequency of 
32.3%, 29%, 35.5% and 37.1% respectively. The p 
value was only significant for falling (p<0.01) when 
comparison was done between frequency of non-motor 
symptoms for mild and severe Parkinson’s Disease. The 
complete list of questions asked and frequency of 
symptoms is listed in Table 1. 
Table 1. Frequency of Non-Motor Symptoms
DISCUSSION
In this study we highlight the overall high frequency of 
NMS in PD in Pakistani population, and their 
comparison between mild and severe disease. Some of 
the components differ in frequency compared to other 
studies carried out around the world which will be 
discussed below.
In our study the highest overall NMS was found to be 
urinary urgency at 74%, comparatively higher than 
other studies. Bonnet et al. in 2012 described the 
urinary urgency in more than 50% of patients and Khoo 
et al. described urinary urgency in spectrum of NMS in 
Early PD at 46 %.6, 10 Constipation was the next 
frequent NMS found in this study at 67.7%. This was 
higher than study of Bonnet et al (45 to 60%), but 
similar to studies by Khoo et al (67%) and Azmin et al 
(67%) who looked at Malaysian population.6, 10, 11 
There was no significant difference between mild versus 
severe disease in our study; however study carried out 
in Italy (PRIAMO), constipation was found to be lower in 
Stage 1 (37%) and much higher in Stage 5 (73%). The 
constipation is treated in PD in usual manner like 
avoiding dehydration, use of laxatives and judicious use 
of fiber. 11
Neuropsychiatric symptoms (low mood and memory 
impairment) involve cholinergic pathways and may 
predate onset of clinical PD with motor symptoms.8, 9, 10, 
11, 12 We found neuropsychiatric symptoms like 
forgetting things and low mood was common (71% and 
62% respectively), with no significant difference 
between mild and severe disease (p 0.47 and 0.6 
respectively) (Table 1). Other studies have reported 
slightly lower incidences of 53-67%.9, 10, 11, 12 The 
dopamine effect is variable on psychiatric domain, with 
some patients responding positively while in others the 
effect remains unpredictable. Depression is linked with 
mortality and morbidity.12, 13, 14 It needs to be addressed 
properly at every stage of Parkinson’s disease and 
should be treated aggressively.
Sexual problems were also reported very high in our 
cohort in the form of decreased libido (67.7%) and 
difficulty in performance (69.4%) with no difference in 
frequency between mild and severe (p 0.7 and 0.2 
respectively) (Table 1). According to Bronner et al., the 
sex problems correlated more with severity of motor 
disease and male gender compared with age, 
depression and use of L-dopa.15 Khoo et al. reported 
significantly lower incidence of impaired libido and 
sexual dysfunction (17% and 28% respectively).10 
Similarly Azmin et al. reported it to be only 8%.11 One 
explanation of such marked difference could be 
different culture and social norms and biases against 
reporting. It is pertinent that this topic should be 
approached with due respect with the patient and 
managed appropriately.16
Among all the NMS, incidence of falling was the only 
reported symptom that was statistically significant (p< 
0.01) between mild and severe disease in our study. 
Fear of falling has been shown to be directly related to 
actual falling.16 Orthostatic hypotension (feeling light 
headed and dizziness) were present in 71%, and falling 
was also common at 66.1%. The incidence of these 
symptoms was extremely low in PRIAMO study (14.2% 
and 1% respectively).12 Khoo et al. reported somewhat 
higher number but still lower than our population (33% 
and 23% respectively).10 Sleep related problems 
(insomnia and Restless Leg Syndrome (RLS) were 
present in frequency of 58.1% and 59.7% (Table 1) 
with no difference in mild and severe disease (p 0.1 
and 0.4 respectively). This is similar to some studies 
such as study in Norwegian population reported 
incidence of sleep problems to be 60%.17,18 Another 
study by Prudon et al. looking at primary sleep disorder 
prevalence in patients with newly diagnosed 
Parkinson's disease reported similar results.19
The prevalence of self-reported hyposmia was only 
23%. This is in contrast to other studies which report 
this finding to be almost universal such as Xiao et al. 
described its prevalence of almost 90% while another 
study by Haehner reported it to be 95%.20, 21 This gross 
difference in the prevalence can be explained by the 
fact that simple question may not reveal the underlying 
problem unless tested by specific kits.21 Since 
hyposmia in recent trials has been shown to be a 
predictor of PD as well as dementia, it suggests a need 
for a better designed screening question for hyposmia 
as it pertains to our population to carry out further 
research in our population. 22, 23, 24
Our study had some limitations including gender bias 
with males being more common than females (ratio 
3:1), slightly more than western population (2:1) and 
likely represent culture bias (men more likely to seek 
treatment). Similarly, we noticed men to be in relatively 
milder disease compared with females. This may 
represent a treatment bias (where females are less 
likely to take medications or seek early treatment) and 
may also represent less access to healthcare by 
females (considered at-risk population). We also used 
a questionnaire not designed or validated in our 
population due to lack of such. The study population 
was small number and having a single site may have 
resulted in selection bias (studying only patients 
presenting to our hospital). 
CONCLUSION
We have shown that non-motor symptoms are 
extremely common in Parkinson’s disease in Pakistani 
population and the frequency of symptoms is similar in 
mild and severe disease except for frequent falls (more 
common in severe Disease)."This is in contrast to 
findings in other population groups with many 
symptoms being much more common in our population 
(such as orthostatic hypotension and falls). Others are 
either lower or more difficult to screen (such as 
hyposmia)." This highlights the strong need for larger 
scale studies to understand the incidence and the likely 
need for a culturally appropriate screening scale for our 
population.
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should be a part of management of PD and there are 
many validated tools available such as Non-Motor 
Symptom Questionnaire (NMSQ), Non-motor 
Symptoms Survey (NMSS),EQ -5D, Parkinson Disease 
Questionnaire(PDQ)39.7
The frequency of non-motor symptoms in Pakistani PD 
population is not known (though assumed to be similar 
to western population). The non-motor symptoms are 
also considered to be a problem of severe disease and 
thus routinely ignored in early disease by practicing 
physicians. In this study we intended to find the 
frequency of non-motor symptoms in Parkinson’s 
Disease and compare frequency between mild and 
severe disease.8,9 
MATERIALS AND METHODS
This study was a cross-sectional, observational, 
descriptive study; carried out on population of PD 
patients presenting to Outpatient clinics at Department 
of Neurology, Pakistan Institute of Medical Sciences 
(PIMS), Islamabad (a Tertiary Care Center). This study 
was internally funded and approved by the local ethics 
committee in accordance with Declaration of Helsinki.
 
All the patients who full-filled the clinical criteria of 
Parkinson’s Disease were included in the study 
according to UK Brain Bank Criteria (Annexure I).10 
Other inclusion parameters were age ≥ 18 years, able 
to give consent and able to answer questions 
independently or with help. Exclusion criteria were 
concern for atypical Parkinson’s, history of psychiatric 
disease or co-morbid conditions that could contribute 
to NMS like diabetes mellitus. Mild Parkinson’s Disease 
was defined as stage I&II of Hoehn and Yahr scale while 
severe disease was defined as stage III, IV & V of Hoehn 
and Yahr scale.11 Informed consent was obtained from 
the patients. The data was recorded with following 
variables: demographic details; age and gender, staging 
of Parkinson’s Disease according to Hoehn and Yahr 
Scale (Figure 1). We used Non-Motor Symptom 
Questionnaire (NMS-Q); a validated scale using 30 
questions related to 9 different domains of symptoms 
(Annexure II). 
The NMS-Q was filled by the patient either 
independently or assisted by family member(s). Where 
there was language problem, the author helped in 
translating the questionnaire to the patient.10
Figure 1: Hoehn &Yahr Scale of PD
Statistical Analysis
Data was analysed through SPSS version 17. The 
numerical data was expressed as mean and standard 
deviation (SD). The categorical data was expressed as 
frequency and percentages. Pearson’s Chi square test 
was used to compare the frequency of NMS in mild and 
severe disease. A p-value of less than 0.05 was 
considered statistically significant.
RESULTS
Statistical Analysis
Data was analysed through SPSS version 17. The 
numerical data was expressed as mean and standard 
deviation (SD). The categorical data was expressed as 
frequency and percentages. Pearson’s Chi square test 
was used to compare the frequency of NMS in mild and 
severe disease. A p-value of less than 0.05 was 
considered statistically significant.
RESULTS
Over the course of the study, 81 patients were 
screened. Those fulfilling the criteria for the study were 
included in the final data set. A total of 62 patients with 
Parkinson’s Disease were recruited over 6 months 
period. The average age was 62.4 ± 11.57 years with 
youngest being 33 years and oldest 80 years of age. 
Males were more common (n=46, 74.1%) then 
females (n=16, 25.8%) with a ration of 3:1.
13 Patients were aged less than 60 (young onset PD) 
including 3 patients in stages II and IV each and 7 in 
stage III. No patient was seen in stage I (likely cultural 
bias, as very early PD does not seek treatment 
potentially from lack of awareness and other 
differences). Majority of patients were above age 60 
(n=49) and had relatively milder disease (59% in stage 
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INTRODUCTION
Parkinson's (PD) is the second most common 
neurodegenerative disorder. Its risk increases with 
advancing age. Parkinson’s Disease has been known 
since ancient times with the earliest mention in Indian 
medical manuscripts Ayeur Veda around 1000BC as 
“Kampavata.” 1, 2 It was named after James Parkinson 
who wrote a detailed monograph titled “an easy on 
shaking palsy” in 1817. 2, 3 European PD association 
estimates prevalence of PD as 6.3 million worldwide, 
affecting all races and cultures. Prevalence in Pakistan 
has been estimated to be 0.4 million by Pakistan 
Parkinson Disease Society. 4
Since its first description to until recently, it’s been 
largely dealt as a motor disease involving dopaminergic 
deficit. However various non-motor symptoms have 
been recognized over the years in PD including 
symptoms of gastrointestinal system, urinary system, 
sleep disturbance, psychiatric, sensory and cognitive 
impairment.5 The exact etiology has not been fully 
elucidated but there is evidence of involvement of 
non-dopaminergic pathways (such as cholinergic and 
serotonergic). Non-motor symptoms often precede 
motor symptoms by up to several decades, most 
commonly olfactory dysfunction (hyposmia), Rapid Eye 
Movement (REM) sleep behavior disorder (RBD), 
constipation, depression, and pain.6 Non-motor 
symptoms may be classified based on neurotransmitter 
pathways involved however most of them involve wide 
spread connections within the brain and thus hard to 
be classified separately. The non- motor symptoms are 
an integral part of the disease but are generally under 
recognized by the treating physician and under reported 
by the patients. Assessment of non-motor symptoms 
I & II) compared to younger population. None were 
seen in Stage 5. Similarly, looking at Stage distribution 
between males and females, males were 
proportionately more in mild disease (Stage I & II) in 
comparison with females (males 60%, females 25%) 
(Figure 2 & 3).
Figure 2: Stages of PD with age distribution
Figure 3: Gender Distribution of severity of PD
The urinary symptoms (urgency and nocturia) were 
most frequent (74.1% and 51.6% respectively) (see 
Table1). The gastro-intestinal symptoms were next in 
frequency with constipation being most common at 
67.7%. Neuropsychiatric symptoms were considerably 
high, including memory problems, low mood, anxiety 
and abnormal libido (71%, 62.9%, 51.6%, 67.7% in 
respective order). Autonomic symptoms like feeling 
light-headed and falling as a result were common (71% 
and 66.1%) while swelling of legs was uncommon at 
29%. Difficulty in performing sex was reported by 
67.7%. The sleep related problems also showed 
significantly high frequency with difficulty staying asleep 
being 58.1% and Restless Leg Syndrome being 59.7%, 
while unexplained pains and unexplained weight 
change were reported to be 61.3% and 38.7% 
respectively. Symptoms like dribbling saliva, double 
vision, dysphagia and hyposmia were in frequency of 
32.3%, 29%, 35.5% and 37.1% respectively. The p 
value was only significant for falling (p<0.01) when 
comparison was done between frequency of non-motor 
symptoms for mild and severe Parkinson’s Disease. The 
complete list of questions asked and frequency of 
symptoms is listed in Table 1. 
Table 1. Frequency of Non-Motor Symptoms
DISCUSSION
In this study we highlight the overall high frequency of 
NMS in PD in Pakistani population, and their 
comparison between mild and severe disease. Some of 
the components differ in frequency compared to other 
studies carried out around the world which will be 
discussed below.
In our study the highest overall NMS was found to be 
urinary urgency at 74%, comparatively higher than 
other studies. Bonnet et al. in 2012 described the 
urinary urgency in more than 50% of patients and Khoo 
et al. described urinary urgency in spectrum of NMS in 
Early PD at 46 %.6, 10 Constipation was the next 
frequent NMS found in this study at 67.7%. This was 
higher than study of Bonnet et al (45 to 60%), but 
similar to studies by Khoo et al (67%) and Azmin et al 
(67%) who looked at Malaysian population.6, 10, 11 
There was no significant difference between mild versus 
severe disease in our study; however study carried out 
in Italy (PRIAMO), constipation was found to be lower in 
Stage 1 (37%) and much higher in Stage 5 (73%). The 
constipation is treated in PD in usual manner like 
avoiding dehydration, use of laxatives and judicious use 
of fiber. 11
Neuropsychiatric symptoms (low mood and memory 
impairment) involve cholinergic pathways and may 
predate onset of clinical PD with motor symptoms.8, 9, 10, 
11, 12 We found neuropsychiatric symptoms like 
forgetting things and low mood was common (71% and 
62% respectively), with no significant difference 
between mild and severe disease (p 0.47 and 0.6 
respectively) (Table 1). Other studies have reported 
slightly lower incidences of 53-67%.9, 10, 11, 12 The 
dopamine effect is variable on psychiatric domain, with 
some patients responding positively while in others the 
effect remains unpredictable. Depression is linked with 
mortality and morbidity.12, 13, 14 It needs to be addressed 
properly at every stage of Parkinson’s disease and 
should be treated aggressively.
Sexual problems were also reported very high in our 
cohort in the form of decreased libido (67.7%) and 
difficulty in performance (69.4%) with no difference in 
frequency between mild and severe (p 0.7 and 0.2 
respectively) (Table 1). According to Bronner et al., the 
sex problems correlated more with severity of motor 
disease and male gender compared with age, 
depression and use of L-dopa.15 Khoo et al. reported 
significantly lower incidence of impaired libido and 
sexual dysfunction (17% and 28% respectively).10 
Similarly Azmin et al. reported it to be only 8%.11 One 
explanation of such marked difference could be 
different culture and social norms and biases against 
reporting. It is pertinent that this topic should be 
approached with due respect with the patient and 
managed appropriately.16
Among all the NMS, incidence of falling was the only 
reported symptom that was statistically significant (p< 
0.01) between mild and severe disease in our study. 
Fear of falling has been shown to be directly related to 
actual falling.16 Orthostatic hypotension (feeling light 
headed and dizziness) were present in 71%, and falling 
was also common at 66.1%. The incidence of these 
symptoms was extremely low in PRIAMO study (14.2% 
and 1% respectively).12 Khoo et al. reported somewhat 
higher number but still lower than our population (33% 
and 23% respectively).10 Sleep related problems 
(insomnia and Restless Leg Syndrome (RLS) were 
present in frequency of 58.1% and 59.7% (Table 1) 
with no difference in mild and severe disease (p 0.1 
and 0.4 respectively). This is similar to some studies 
such as study in Norwegian population reported 
incidence of sleep problems to be 60%.17,18 Another 
study by Prudon et al. looking at primary sleep disorder 
prevalence in patients with newly diagnosed 
Parkinson's disease reported similar results.19
The prevalence of self-reported hyposmia was only 
23%. This is in contrast to other studies which report 
this finding to be almost universal such as Xiao et al. 
described its prevalence of almost 90% while another 
study by Haehner reported it to be 95%.20, 21 This gross 
difference in the prevalence can be explained by the 
fact that simple question may not reveal the underlying 
problem unless tested by specific kits.21 Since 
hyposmia in recent trials has been shown to be a 
predictor of PD as well as dementia, it suggests a need 
for a better designed screening question for hyposmia 
as it pertains to our population to carry out further 
research in our population. 22, 23, 24
Our study had some limitations including gender bias 
with males being more common than females (ratio 
3:1), slightly more than western population (2:1) and 
likely represent culture bias (men more likely to seek 
treatment). Similarly, we noticed men to be in relatively 
milder disease compared with females. This may 
represent a treatment bias (where females are less 
likely to take medications or seek early treatment) and 
may also represent less access to healthcare by 
females (considered at-risk population). We also used 
a questionnaire not designed or validated in our 
population due to lack of such. The study population 
was small number and having a single site may have 
resulted in selection bias (studying only patients 
presenting to our hospital). 
CONCLUSION
We have shown that non-motor symptoms are 
extremely common in Parkinson’s disease in Pakistani 
population and the frequency of symptoms is similar in 
mild and severe disease except for frequent falls (more 
common in severe Disease)."This is in contrast to 
findings in other population groups with many 
symptoms being much more common in our population 
(such as orthostatic hypotension and falls). Others are 
either lower or more difficult to screen (such as 
hyposmia)." This highlights the strong need for larger 
scale studies to understand the incidence and the likely 
need for a culturally appropriate screening scale for our 
population.
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should be a part of management of PD and there are 
many validated tools available such as Non-Motor 
Symptom Questionnaire (NMSQ), Non-motor 
Symptoms Survey (NMSS),EQ -5D, Parkinson Disease 
Questionnaire(PDQ)39.7
The frequency of non-motor symptoms in Pakistani PD 
population is not known (though assumed to be similar 
to western population). The non-motor symptoms are 
also considered to be a problem of severe disease and 
thus routinely ignored in early disease by practicing 
physicians. In this study we intended to find the 
frequency of non-motor symptoms in Parkinson’s 
Disease and compare frequency between mild and 
severe disease.8,9 
MATERIALS AND METHODS
This study was a cross-sectional, observational, 
descriptive study; carried out on population of PD 
patients presenting to Outpatient clinics at Department 
of Neurology, Pakistan Institute of Medical Sciences 
(PIMS), Islamabad (a Tertiary Care Center). This study 
was internally funded and approved by the local ethics 
committee in accordance with Declaration of Helsinki.
 
All the patients who full-filled the clinical criteria of 
Parkinson’s Disease were included in the study 
according to UK Brain Bank Criteria (Annexure I).10 
Other inclusion parameters were age ≥ 18 years, able 
to give consent and able to answer questions 
independently or with help. Exclusion criteria were 
concern for atypical Parkinson’s, history of psychiatric 
disease or co-morbid conditions that could contribute 
to NMS like diabetes mellitus. Mild Parkinson’s Disease 
was defined as stage I&II of Hoehn and Yahr scale while 
severe disease was defined as stage III, IV & V of Hoehn 
and Yahr scale.11 Informed consent was obtained from 
the patients. The data was recorded with following 
variables: demographic details; age and gender, staging 
of Parkinson’s Disease according to Hoehn and Yahr 
Scale (Figure 1). We used Non-Motor Symptom 
Questionnaire (NMS-Q); a validated scale using 30 
questions related to 9 different domains of symptoms 
(Annexure II). 
The NMS-Q was filled by the patient either 
independently or assisted by family member(s). Where 
there was language problem, the author helped in 
translating the questionnaire to the patient.10
Figure 1: Hoehn &Yahr Scale of PD
Statistical Analysis
Data was analysed through SPSS version 17. The 
numerical data was expressed as mean and standard 
deviation (SD). The categorical data was expressed as 
frequency and percentages. Pearson’s Chi square test 
was used to compare the frequency of NMS in mild and 
severe disease. A p-value of less than 0.05 was 
considered statistically significant.
RESULTS
Statistical Analysis
Data was analysed through SPSS version 17. The 
numerical data was expressed as mean and standard 
deviation (SD). The categorical data was expressed as 
frequency and percentages. Pearson’s Chi square test 
was used to compare the frequency of NMS in mild and 
severe disease. A p-value of less than 0.05 was 
considered statistically significant.
RESULTS
Over the course of the study, 81 patients were 
screened. Those fulfilling the criteria for the study were 
included in the final data set. A total of 62 patients with 
Parkinson’s Disease were recruited over 6 months 
period. The average age was 62.4 ± 11.57 years with 
youngest being 33 years and oldest 80 years of age. 
Males were more common (n=46, 74.1%) then 
females (n=16, 25.8%) with a ration of 3:1.
13 Patients were aged less than 60 (young onset PD) 
including 3 patients in stages II and IV each and 7 in 
stage III. No patient was seen in stage I (likely cultural 
bias, as very early PD does not seek treatment 
potentially from lack of awareness and other 
differences). Majority of patients were above age 60 
(n=49) and had relatively milder disease (59% in stage 
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INTRODUCTION
Parkinson's (PD) is the second most common 
neurodegenerative disorder. Its risk increases with 
advancing age. Parkinson’s Disease has been known 
since ancient times with the earliest mention in Indian 
medical manuscripts Ayeur Veda around 1000BC as 
“Kampavata.” 1, 2 It was named after James Parkinson 
who wrote a detailed monograph titled “an easy on 
shaking palsy” in 1817. 2, 3 European PD association 
estimates prevalence of PD as 6.3 million worldwide, 
affecting all races and cultures. Prevalence in Pakistan 
has been estimated to be 0.4 million by Pakistan 
Parkinson Disease Society. 4
Since its first description to until recently, it’s been 
largely dealt as a motor disease involving dopaminergic 
deficit. However various non-motor symptoms have 
been recognized over the years in PD including 
symptoms of gastrointestinal system, urinary system, 
sleep disturbance, psychiatric, sensory and cognitive 
impairment.5 The exact etiology has not been fully 
elucidated but there is evidence of involvement of 
non-dopaminergic pathways (such as cholinergic and 
serotonergic). Non-motor symptoms often precede 
motor symptoms by up to several decades, most 
commonly olfactory dysfunction (hyposmia), Rapid Eye 
Movement (REM) sleep behavior disorder (RBD), 
constipation, depression, and pain.6 Non-motor 
symptoms may be classified based on neurotransmitter 
pathways involved however most of them involve wide 
spread connections within the brain and thus hard to 
be classified separately. The non- motor symptoms are 
an integral part of the disease but are generally under 
recognized by the treating physician and under reported 
by the patients. Assessment of non-motor symptoms 
I & II) compared to younger population. None were 
seen in Stage 5. Similarly, looking at Stage distribution 
between males and females, males were 
proportionately more in mild disease (Stage I & II) in 
comparison with females (males 60%, females 25%) 
(Figure 2 & 3).
Figure 2: Stages of PD with age distribution
Figure 3: Gender Distribution of severity of PD
The urinary symptoms (urgency and nocturia) were 
most frequent (74.1% and 51.6% respectively) (see 
Table1). The gastro-intestinal symptoms were next in 
frequency with constipation being most common at 
67.7%. Neuropsychiatric symptoms were considerably 
high, including memory problems, low mood, anxiety 
and abnormal libido (71%, 62.9%, 51.6%, 67.7% in 
respective order). Autonomic symptoms like feeling 
light-headed and falling as a result were common (71% 
and 66.1%) while swelling of legs was uncommon at 
29%. Difficulty in performing sex was reported by 
67.7%. The sleep related problems also showed 
significantly high frequency with difficulty staying asleep 
being 58.1% and Restless Leg Syndrome being 59.7%, 
while unexplained pains and unexplained weight 
change were reported to be 61.3% and 38.7% 
respectively. Symptoms like dribbling saliva, double 
vision, dysphagia and hyposmia were in frequency of 
32.3%, 29%, 35.5% and 37.1% respectively. The p 
value was only significant for falling (p<0.01) when 
comparison was done between frequency of non-motor 
symptoms for mild and severe Parkinson’s Disease. The 
complete list of questions asked and frequency of 
symptoms is listed in Table 1. 
Table 1. Frequency of Non-Motor Symptoms
DISCUSSION
In this study we highlight the overall high frequency of 
NMS in PD in Pakistani population, and their 
comparison between mild and severe disease. Some of 
the components differ in frequency compared to other 
studies carried out around the world which will be 
discussed below.
In our study the highest overall NMS was found to be 
urinary urgency at 74%, comparatively higher than 
other studies. Bonnet et al. in 2012 described the 
urinary urgency in more than 50% of patients and Khoo 
et al. described urinary urgency in spectrum of NMS in 
Early PD at 46 %.6, 10 Constipation was the next 
frequent NMS found in this study at 67.7%. This was 
higher than study of Bonnet et al (45 to 60%), but 
similar to studies by Khoo et al (67%) and Azmin et al 
(67%) who looked at Malaysian population.6, 10, 11 
There was no significant difference between mild versus 
severe disease in our study; however study carried out 
in Italy (PRIAMO), constipation was found to be lower in 
Stage 1 (37%) and much higher in Stage 5 (73%). The 
constipation is treated in PD in usual manner like 
avoiding dehydration, use of laxatives and judicious use 
of fiber. 11
Neuropsychiatric symptoms (low mood and memory 
impairment) involve cholinergic pathways and may 
predate onset of clinical PD with motor symptoms.8, 9, 10, 
11, 12 We found neuropsychiatric symptoms like 
forgetting things and low mood was common (71% and 
62% respectively), with no significant difference 
between mild and severe disease (p 0.47 and 0.6 
respectively) (Table 1). Other studies have reported 
slightly lower incidences of 53-67%.9, 10, 11, 12 The 
dopamine effect is variable on psychiatric domain, with 
some patients responding positively while in others the 
effect remains unpredictable. Depression is linked with 
mortality and morbidity.12, 13, 14 It needs to be addressed 
properly at every stage of Parkinson’s disease and 
should be treated aggressively.
Sexual problems were also reported very high in our 
cohort in the form of decreased libido (67.7%) and 
difficulty in performance (69.4%) with no difference in 
frequency between mild and severe (p 0.7 and 0.2 
respectively) (Table 1). According to Bronner et al., the 
sex problems correlated more with severity of motor 
disease and male gender compared with age, 
depression and use of L-dopa.15 Khoo et al. reported 
significantly lower incidence of impaired libido and 
sexual dysfunction (17% and 28% respectively).10 
Similarly Azmin et al. reported it to be only 8%.11 One 
explanation of such marked difference could be 
different culture and social norms and biases against 
reporting. It is pertinent that this topic should be 
approached with due respect with the patient and 
managed appropriately.16
Among all the NMS, incidence of falling was the only 
reported symptom that was statistically significant (p< 
0.01) between mild and severe disease in our study. 
Fear of falling has been shown to be directly related to 
actual falling.16 Orthostatic hypotension (feeling light 
headed and dizziness) were present in 71%, and falling 
was also common at 66.1%. The incidence of these 
symptoms was extremely low in PRIAMO study (14.2% 
and 1% respectively).12 Khoo et al. reported somewhat 
higher number but still lower than our population (33% 
and 23% respectively).10 Sleep related problems 
(insomnia and Restless Leg Syndrome (RLS) were 
present in frequency of 58.1% and 59.7% (Table 1) 
with no difference in mild and severe disease (p 0.1 
and 0.4 respectively). This is similar to some studies 
such as study in Norwegian population reported 
incidence of sleep problems to be 60%.17,18 Another 
study by Prudon et al. looking at primary sleep disorder 
prevalence in patients with newly diagnosed 
Parkinson's disease reported similar results.19
The prevalence of self-reported hyposmia was only 
23%. This is in contrast to other studies which report 
this finding to be almost universal such as Xiao et al. 
described its prevalence of almost 90% while another 
study by Haehner reported it to be 95%.20, 21 This gross 
difference in the prevalence can be explained by the 
fact that simple question may not reveal the underlying 
problem unless tested by specific kits.21 Since 
hyposmia in recent trials has been shown to be a 
predictor of PD as well as dementia, it suggests a need 
for a better designed screening question for hyposmia 
as it pertains to our population to carry out further 
research in our population. 22, 23, 24
Our study had some limitations including gender bias 
with males being more common than females (ratio 
3:1), slightly more than western population (2:1) and 
likely represent culture bias (men more likely to seek 
treatment). Similarly, we noticed men to be in relatively 
milder disease compared with females. This may 
represent a treatment bias (where females are less 
likely to take medications or seek early treatment) and 
may also represent less access to healthcare by 
females (considered at-risk population). We also used 
a questionnaire not designed or validated in our 
population due to lack of such. The study population 
was small number and having a single site may have 
resulted in selection bias (studying only patients 
presenting to our hospital). 
CONCLUSION
We have shown that non-motor symptoms are 
extremely common in Parkinson’s disease in Pakistani 
population and the frequency of symptoms is similar in 
mild and severe disease except for frequent falls (more 
common in severe Disease)."This is in contrast to 
findings in other population groups with many 
symptoms being much more common in our population 
(such as orthostatic hypotension and falls). Others are 
either lower or more difficult to screen (such as 
hyposmia)." This highlights the strong need for larger 
scale studies to understand the incidence and the likely 
need for a culturally appropriate screening scale for our 
population.
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should be a part of management of PD and there are 
many validated tools available such as Non-Motor 
Symptom Questionnaire (NMSQ), Non-motor 
Symptoms Survey (NMSS),EQ -5D, Parkinson Disease 
Questionnaire(PDQ)39.7
The frequency of non-motor symptoms in Pakistani PD 
population is not known (though assumed to be similar 
to western population). The non-motor symptoms are 
also considered to be a problem of severe disease and 
thus routinely ignored in early disease by practicing 
physicians. In this study we intended to find the 
frequency of non-motor symptoms in Parkinson’s 
Disease and compare frequency between mild and 
severe disease.8,9 
MATERIALS AND METHODS
This study was a cross-sectional, observational, 
descriptive study; carried out on population of PD 
patients presenting to Outpatient clinics at Department 
of Neurology, Pakistan Institute of Medical Sciences 
(PIMS), Islamabad (a Tertiary Care Center). This study 
was internally funded and approved by the local ethics 
committee in accordance with Declaration of Helsinki.
 
All the patients who full-filled the clinical criteria of 
Parkinson’s Disease were included in the study 
according to UK Brain Bank Criteria (Annexure I).10 
Other inclusion parameters were age ≥ 18 years, able 
to give consent and able to answer questions 
independently or with help. Exclusion criteria were 
concern for atypical Parkinson’s, history of psychiatric 
disease or co-morbid conditions that could contribute 
to NMS like diabetes mellitus. Mild Parkinson’s Disease 
was defined as stage I&II of Hoehn and Yahr scale while 
severe disease was defined as stage III, IV & V of Hoehn 
and Yahr scale.11 Informed consent was obtained from 
the patients. The data was recorded with following 
variables: demographic details; age and gender, staging 
of Parkinson’s Disease according to Hoehn and Yahr 
Scale (Figure 1). We used Non-Motor Symptom 
Questionnaire (NMS-Q); a validated scale using 30 
questions related to 9 different domains of symptoms 
(Annexure II). 
The NMS-Q was filled by the patient either 
independently or assisted by family member(s). Where 
there was language problem, the author helped in 
translating the questionnaire to the patient.10
Figure 1: Hoehn &Yahr Scale of PD
Statistical Analysis
Data was analysed through SPSS version 17. The 
numerical data was expressed as mean and standard 
deviation (SD). The categorical data was expressed as 
frequency and percentages. Pearson’s Chi square test 
was used to compare the frequency of NMS in mild and 
severe disease. A p-value of less than 0.05 was 
considered statistically significant.
RESULTS
Statistical Analysis
Data was analysed through SPSS version 17. The 
numerical data was expressed as mean and standard 
deviation (SD). The categorical data was expressed as 
frequency and percentages. Pearson’s Chi square test 
was used to compare the frequency of NMS in mild and 
severe disease. A p-value of less than 0.05 was 
considered statistically significant.
RESULTS
Over the course of the study, 81 patients were 
screened. Those fulfilling the criteria for the study were 
included in the final data set. A total of 62 patients with 
Parkinson’s Disease were recruited over 6 months 
period. The average age was 62.4 ± 11.57 years with 
youngest being 33 years and oldest 80 years of age. 
Males were more common (n=46, 74.1%) then 
females (n=16, 25.8%) with a ration of 3:1.
13 Patients were aged less than 60 (young onset PD) 
including 3 patients in stages II and IV each and 7 in 
stage III. No patient was seen in stage I (likely cultural 
bias, as very early PD does not seek treatment 
potentially from lack of awareness and other 
differences). Majority of patients were above age 60 
(n=49) and had relatively milder disease (59% in stage 
INTRODUCTION
Parkinson's (PD) is the second most common 
neurodegenerative disorder. Its risk increases with 
advancing age. Parkinson’s Disease has been known 
since ancient times with the earliest mention in Indian 
medical manuscripts Ayeur Veda around 1000BC as 
“Kampavata.” 1, 2 It was named after James Parkinson 
who wrote a detailed monograph titled “an easy on 
shaking palsy” in 1817. 2, 3 European PD association 
estimates prevalence of PD as 6.3 million worldwide, 
affecting all races and cultures. Prevalence in Pakistan 
has been estimated to be 0.4 million by Pakistan 
Parkinson Disease Society. 4
Since its first description to until recently, it’s been 
largely dealt as a motor disease involving dopaminergic 
deficit. However various non-motor symptoms have 
been recognized over the years in PD including 
symptoms of gastrointestinal system, urinary system, 
sleep disturbance, psychiatric, sensory and cognitive 
impairment.5 The exact etiology has not been fully 
elucidated but there is evidence of involvement of 
non-dopaminergic pathways (such as cholinergic and 
serotonergic). Non-motor symptoms often precede 
motor symptoms by up to several decades, most 
commonly olfactory dysfunction (hyposmia), Rapid Eye 
Movement (REM) sleep behavior disorder (RBD), 
constipation, depression, and pain.6 Non-motor 
symptoms may be classified based on neurotransmitter 
pathways involved however most of them involve wide 
spread connections within the brain and thus hard to 
be classified separately. The non- motor symptoms are 
an integral part of the disease but are generally under 
recognized by the treating physician and under reported 
by the patients. Assessment of non-motor symptoms 
I & II) compared to younger population. None were 
seen in Stage 5. Similarly, looking at Stage distribution 
between males and females, males were 
proportionately more in mild disease (Stage I & II) in 
comparison with females (males 60%, females 25%) 
(Figure 2 & 3).
Figure 2: Stages of PD with age distribution
Figure 3: Gender Distribution of severity of PD
The urinary symptoms (urgency and nocturia) were 
most frequent (74.1% and 51.6% respectively) (see 
Table1). The gastro-intestinal symptoms were next in 
frequency with constipation being most common at 
67.7%. Neuropsychiatric symptoms were considerably 
high, including memory problems, low mood, anxiety 
and abnormal libido (71%, 62.9%, 51.6%, 67.7% in 
respective order). Autonomic symptoms like feeling 
light-headed and falling as a result were common (71% 
and 66.1%) while swelling of legs was uncommon at 
29%. Difficulty in performing sex was reported by 
67.7%. The sleep related problems also showed 
significantly high frequency with difficulty staying asleep 
being 58.1% and Restless Leg Syndrome being 59.7%, 
while unexplained pains and unexplained weight 
change were reported to be 61.3% and 38.7% 
respectively. Symptoms like dribbling saliva, double 
vision, dysphagia and hyposmia were in frequency of 
32.3%, 29%, 35.5% and 37.1% respectively. The p 
value was only significant for falling (p<0.01) when 
comparison was done between frequency of non-motor 
symptoms for mild and severe Parkinson’s Disease. The 
complete list of questions asked and frequency of 
symptoms is listed in Table 1. 
Table 1. Frequency of Non-Motor Symptoms
DISCUSSION
In this study we highlight the overall high frequency of 
NMS in PD in Pakistani population, and their 
comparison between mild and severe disease. Some of 
the components differ in frequency compared to other 
studies carried out around the world which will be 
discussed below.
In our study the highest overall NMS was found to be 
urinary urgency at 74%, comparatively higher than 
other studies. Bonnet et al. in 2012 described the 
urinary urgency in more than 50% of patients and Khoo 
et al. described urinary urgency in spectrum of NMS in 
Early PD at 46 %.6, 10 Constipation was the next 
frequent NMS found in this study at 67.7%. This was 
higher than study of Bonnet et al (45 to 60%), but 
similar to studies by Khoo et al (67%) and Azmin et al 
(67%) who looked at Malaysian population.6, 10, 11 
There was no significant difference between mild versus 
severe disease in our study; however study carried out 
in Italy (PRIAMO), constipation was found to be lower in 
Stage 1 (37%) and much higher in Stage 5 (73%). The 
constipation is treated in PD in usual manner like 
avoiding dehydration, use of laxatives and judicious use 
of fiber. 11
Neuropsychiatric symptoms (low mood and memory 
impairment) involve cholinergic pathways and may 
predate onset of clinical PD with motor symptoms.8, 9, 10, 
11, 12 We found neuropsychiatric symptoms like 
forgetting things and low mood was common (71% and 
62% respectively), with no significant difference 
between mild and severe disease (p 0.47 and 0.6 
respectively) (Table 1). Other studies have reported 
slightly lower incidences of 53-67%.9, 10, 11, 12 The 
dopamine effect is variable on psychiatric domain, with 
some patients responding positively while in others the 
effect remains unpredictable. Depression is linked with 
mortality and morbidity.12, 13, 14 It needs to be addressed 
properly at every stage of Parkinson’s disease and 
should be treated aggressively.
Sexual problems were also reported very high in our 
cohort in the form of decreased libido (67.7%) and 
difficulty in performance (69.4%) with no difference in 
frequency between mild and severe (p 0.7 and 0.2 
respectively) (Table 1). According to Bronner et al., the 
sex problems correlated more with severity of motor 
disease and male gender compared with age, 
depression and use of L-dopa.15 Khoo et al. reported 
significantly lower incidence of impaired libido and 
sexual dysfunction (17% and 28% respectively).10 
Similarly Azmin et al. reported it to be only 8%.11 One 
explanation of such marked difference could be 
different culture and social norms and biases against 
reporting. It is pertinent that this topic should be 
approached with due respect with the patient and 
managed appropriately.16
Among all the NMS, incidence of falling was the only 
reported symptom that was statistically significant (p< 
0.01) between mild and severe disease in our study. 
Fear of falling has been shown to be directly related to 
actual falling.16 Orthostatic hypotension (feeling light 
headed and dizziness) were present in 71%, and falling 
was also common at 66.1%. The incidence of these 
symptoms was extremely low in PRIAMO study (14.2% 
and 1% respectively).12 Khoo et al. reported somewhat 
higher number but still lower than our population (33% 
and 23% respectively).10 Sleep related problems 
(insomnia and Restless Leg Syndrome (RLS) were 
present in frequency of 58.1% and 59.7% (Table 1) 
with no difference in mild and severe disease (p 0.1 
and 0.4 respectively). This is similar to some studies 
such as study in Norwegian population reported 
incidence of sleep problems to be 60%.17,18 Another 
study by Prudon et al. looking at primary sleep disorder 
prevalence in patients with newly diagnosed 
Parkinson's disease reported similar results.19
The prevalence of self-reported hyposmia was only 
23%. This is in contrast to other studies which report 
this finding to be almost universal such as Xiao et al. 
described its prevalence of almost 90% while another 
study by Haehner reported it to be 95%.20, 21 This gross 
difference in the prevalence can be explained by the 
fact that simple question may not reveal the underlying 
problem unless tested by specific kits.21 Since 
hyposmia in recent trials has been shown to be a 
predictor of PD as well as dementia, it suggests a need 
for a better designed screening question for hyposmia 
as it pertains to our population to carry out further 
research in our population. 22, 23, 24
Our study had some limitations including gender bias 
with males being more common than females (ratio 
3:1), slightly more than western population (2:1) and 
likely represent culture bias (men more likely to seek 
treatment). Similarly, we noticed men to be in relatively 
milder disease compared with females. This may 
represent a treatment bias (where females are less 
likely to take medications or seek early treatment) and 
may also represent less access to healthcare by 
females (considered at-risk population). We also used 
a questionnaire not designed or validated in our 
population due to lack of such. The study population 
was small number and having a single site may have 
resulted in selection bias (studying only patients 
presenting to our hospital). 
CONCLUSION
We have shown that non-motor symptoms are 
extremely common in Parkinson’s disease in Pakistani 
population and the frequency of symptoms is similar in 
mild and severe disease except for frequent falls (more 
common in severe Disease)."This is in contrast to 
findings in other population groups with many 
symptoms being much more common in our population 
(such as orthostatic hypotension and falls). Others are 
either lower or more difficult to screen (such as 
hyposmia)." This highlights the strong need for larger 
scale studies to understand the incidence and the likely 
need for a culturally appropriate screening scale for our 
population.
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should be a part of management of PD and there are 
many validated tools available such as Non-Motor 
Symptom Questionnaire (NMSQ), Non-motor 
Symptoms Survey (NMSS),EQ -5D, Parkinson Disease 
Questionnaire(PDQ)39.7
The frequency of non-motor symptoms in Pakistani PD 
population is not known (though assumed to be similar 
to western population). The non-motor symptoms are 
also considered to be a problem of severe disease and 
thus routinely ignored in early disease by practicing 
physicians. In this study we intended to find the 
frequency of non-motor symptoms in Parkinson’s 
Disease and compare frequency between mild and 
severe disease.8,9 
MATERIALS AND METHODS
This study was a cross-sectional, observational, 
descriptive study; carried out on population of PD 
patients presenting to Outpatient clinics at Department 
of Neurology, Pakistan Institute of Medical Sciences 
(PIMS), Islamabad (a Tertiary Care Center). This study 
was internally funded and approved by the local ethics 
committee in accordance with Declaration of Helsinki.
 
All the patients who full-filled the clinical criteria of 
Parkinson’s Disease were included in the study 
according to UK Brain Bank Criteria (Annexure I).10 
Other inclusion parameters were age ≥ 18 years, able 
to give consent and able to answer questions 
independently or with help. Exclusion criteria were 
concern for atypical Parkinson’s, history of psychiatric 
disease or co-morbid conditions that could contribute 
to NMS like diabetes mellitus. Mild Parkinson’s Disease 
was defined as stage I&II of Hoehn and Yahr scale while 
severe disease was defined as stage III, IV & V of Hoehn 
and Yahr scale.11 Informed consent was obtained from 
the patients. The data was recorded with following 
variables: demographic details; age and gender, staging 
of Parkinson’s Disease according to Hoehn and Yahr 
Scale (Figure 1). We used Non-Motor Symptom 
Questionnaire (NMS-Q); a validated scale using 30 
questions related to 9 different domains of symptoms 
(Annexure II). 
The NMS-Q was filled by the patient either 
independently or assisted by family member(s). Where 
there was language problem, the author helped in 
translating the questionnaire to the patient.10
Figure 1: Hoehn &Yahr Scale of PD
Statistical Analysis
Data was analysed through SPSS version 17. The 
numerical data was expressed as mean and standard 
deviation (SD). The categorical data was expressed as 
frequency and percentages. Pearson’s Chi square test 
was used to compare the frequency of NMS in mild and 
severe disease. A p-value of less than 0.05 was 
considered statistically significant.
RESULTS
Statistical Analysis
Data was analysed through SPSS version 17. The 
numerical data was expressed as mean and standard 
deviation (SD). The categorical data was expressed as 
frequency and percentages. Pearson’s Chi square test 
was used to compare the frequency of NMS in mild and 
severe disease. A p-value of less than 0.05 was 
considered statistically significant.
RESULTS
Over the course of the study, 81 patients were 
screened. Those fulfilling the criteria for the study were 
included in the final data set. A total of 62 patients with 
Parkinson’s Disease were recruited over 6 months 
period. The average age was 62.4 ± 11.57 years with 
youngest being 33 years and oldest 80 years of age. 
Males were more common (n=46, 74.1%) then 
females (n=16, 25.8%) with a ration of 3:1.
13 Patients were aged less than 60 (young onset PD) 
including 3 patients in stages II and IV each and 7 in 
stage III. No patient was seen in stage I (likely cultural 
bias, as very early PD does not seek treatment 
potentially from lack of awareness and other 
differences). Majority of patients were above age 60 
(n=49) and had relatively milder disease (59% in stage 
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